Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mei Pharma Inc (NQ: MEIP )

3.010 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.010
Bid (Size) 2.900 (3)
Ask (Size) 3.260 (1)
Prev. Close 3.010
Today's Range 3.010 - 3.010
52wk Range 2.610 - 7.873
Shares Outstanding 6,662,857
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
From MEI Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
-49.92%
-49.92%
1 Month
+11.07%
+11.07%
3 Month
-5.05%
-5.05%
6 Month
+2.73%
+2.73%
1 Year
-61.61%
-61.61%

More News

Read More
MEI Pharma Reports Fiscal Year End 2024 Cash Position
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
From MEI Pharma, Inc.
Via Business Wire
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
MEI Pharma to Consider Strategic Alternatives
From MEI Pharma, Inc.
Via Business Wire
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
From Glancy Prongay & Murray LLP
Via Business Wire
MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024
Via InvestorPlace
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
From MEI Pharma, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
From Glancy Prongay & Murray LLP
Via Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
From MEI Pharma, Inc.
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
From Glancy Prongay & Murray LLP
Via Business Wire
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
From MEI Pharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
From MEI Pharma, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.